DOCSLIB.ORG

Preparing for Access to PRO 2000 Microbicide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preparing for Access to PRO 2000 Microbicide WHO/RHR/10.19 Preparing for access to PRO 2000 microbicide Report of a meeting 27–28 May 2009, London, United Kingdom World Health Organization and UNAIDS Meeting report Meeting report Contents Acknowledgements 3 Executive summary 3 Acronyms and abbreviations 4 Background 5 What do (and can) we know about PRO 2000 from the HPTN 035 and MDP 301 trials? 6 Safety and effectiveness 6 Further studies and analyses 6 Acceptability and users’ perspectives 6 Additional clinical research 7 Product ownership and licensing 7 Cost 8 Manufacturing 8 Regulatory review 9 Carcinogenicity study 10 Policy and programmes 10 Level of effectiveness 10 Modelling 11 Donors 12 WHO recommendations 12 Implications for other prevention trials 13 Strategic communications and messaging 13 Scientists 14 Policy-makers 14 Trial communities 14 Next steps 14 Appendix 1: Contingency planning list for PRO 2000 access 15 Appendix 2: Timeline for PRO 2000 access 21 Appendix 3: List of participants 22 Preparing for access to PRO 2000 microbicide Note: Since this report was prepared, the results of the MDP 301 study were announced on 14 December 2009 and published in The Lancet on 20 September 2010. (http://dx.doi.org/10.1016/S0140-6736(10)61086-0). The study showed no benefit of 0.5% PRO2000 in reducing the risk of HIV infection. All further development and investment in the product has ceased. Preparing for access to PRO 2000 microbicide © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Preparing for access to PRO 2000 microbicide Preparing for access to PRO 2000 microbicide Acknowledgements This report was prepared by Elizabeth McGrory (WHO consultant) and Tim Farley (WHO). Executive summary In February 2009, the Microbicide Trials Network (MTN) announced that its HIV Prevention Trials Network (HPTN) 035 trial showed a 30% reduction in human immunodeficiency virus (HIV) incidence in women using the microbicide PRO 2000 compared with placebo gel. This reduction in risk was not statistically significant. There were no safety concerns associated with the product and it was highly acceptable to users. PRO 2000 is also being tested in a second trial by the Microbicides Development Programme (MDP) group, with results expected in late 2009. The MDP 301 trial is larger than the HPTN 035 trial, and if it shows a similar level of risk reduction and confirms that the product is safe, PRO 2000 will be the first microbicide shown to be safe and effective in reducing the risk of HIV acquisition. If the MDP 301 trial does confirm the HPTN 035 results, this will mark the beginning of a long and complicated process to make the product available to women at risk of HIV infection. The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened key actors involved in the microbicide field to identify and prioritize actions needed to prepare for access to PRO 2000. This meeting, held in London, 27–28 May 2009, was designed to: • review the results of impact models under different assumptions relating to effectiveness and imputed efficacy, targeting, and coverage, in order to inform policy recommendations and priority groups for access; • review plans and identify gaps for scale-up and availability of PRO 2000 gel, under the assumption that the second trial confirms safety and effectiveness; • identify and prioritize actions, roles and responsibilities of different actors, including a timeline and potential funding sources, for both the near and long term. Key issues that emerged during the presentations and discussion include: • Endo Pharmaceuticals acquired PRO 2000 in March 2009 and is evaluating the product’s fit in its portfolio; • the agreement between Endo and the UK Medical Research Council (MRC), sponsor of the MDP 301 trial, includes a provision for a “cost-plus” pricing structure in low-income economies. It also grants the MRC or its agents the right to manufacture and distribute the product for use in low-income economies if Endo does not develop it further; • if PRO 2000 is shown to be safe and effective, it is not clear whether Endo will develop the product, out-license to another private company, or license to a not-for-profit organization; • uncertainty around which entity will eventually develop PRO 2000 if shown to be safe and effective is hampering further development of and investment in the product; this has particular relevance to determining the best path to licensure, initiating further high-priority research, investment in scaled- up manufacturing, and other related issues; • it is important to build consensus around what level of effectiveness would warrant further investment in and development of PRO 2000. A wide range of views existed among participants at the consultation, who represented diverse constituencies within the microbicide and HIV-prevention fields, with their own sets of priorities. It is important also to engage other key constituencies, including national policy-makers and regulatory authorities, as well as women at risk of HIV infection who are the ultimate beneficiaries of microbicide-development efforts; • any regulatory submission is likely to take at least two years after the MDP 301 results are released, based on the need to validate scaled-up manufacturing and provide process and stability data, as well as completing additional safety and/or acceptability studies that may be required; 3 Preparing for access to PRO 2000 microbicide • there is a limited amount of PRO 2000 currently available for additional clinical and pre-introductory studies, so it will be necessary to prioritize how the available PRO 2000 will be used, balancing the need to answer priority research questions and any obligations (implicit or explicit) to trial participants and/or communities; • the microbicide field must work out how to convey clear and accurate messages about what the results of the MDP 301 trial mean for PRO 2000, for other microbicide research, and for HIV- prevention research. If PRO 2000 is going to be developed further, these messages need to clearly state plans for further research and access at the HPTN 035 and MDP 301 trial sites, and realistic timeframes and scenarios for more widespread access. Messaging must also be very clear, if the MDP 301 results do not support further investment in and development of PRO 2000, particularly if an encouraging, though not convincing, result emerges. Participants identified and prioritized action items and next steps, including, when possible, which agency or group would be responsible for following up, potential funding sources, and the timeframe (see Appendixes 1 and 2). WHO will play a coordinating role in tracking, monitoring and facilitating these follow-up activities. Acronyms and abbreviations AIDS acquired immunodeficiency syndrome ARV antiretroviral CROI Conference on Retroviruses and Opportunistic Infections DFID Department for International Development EMA European Medicines Agency FDA Food and Drug Administration HIV human immunodeficiency virus HPTN HIV Prevention Trials Network HPV human papillomavirus IPM International Partnership for Microbicides MCC Medicines Control Council MMCI Microbicides Media and Communications Initiative MRC Medical Research Council MDP Microbicides Development Programme MTN Microbicide Trials Network NIAID National Institute of Allergy and Infectious Diseases NIH National Institutes of Health PEPFAR President’s Emergency Plan for AIDS Relief SADC Southern African Development Community STI sexually transmitted infection TB tuberculosis UNAIDS Joint United Nations Programme on HIV/AIDS USA United States of America WHO World Health Organization 4 Preparing for access to PRO 2000 microbicide Preparing for access to PRO 2000 microbicide Background At the February 2009 Conference on Retroviruses and Opportunistic Infections (CROI), the Microbicide Trials Network (MTN) announced that its HIV Prevention
Load more

Recommended publications
  • RESEARCH a Forum for Putting Knowledge Into Practice July 2008 Volume 2, Issue 2
    FAMILY HEALTH RESEARCH A forum for putting knowledge into practice JULY 2008 VOLUME 2, ISSUE 2 INSIDE 2 Clinical research update 4 Evaluating tenofovir gel in South Africa 6 Participating in microbicide trials 7 Preparing for microbicides 8 Research and advocacy partnerships sub-Saharan Africa still suffers the most from MICROBICIDES the epidemic. More than two-thirds of all HIV- FOR HIV infected people in the world live in this region. Of these, more than 60 percent are women. PREVENTION Young women are even more disproportion- ately affected. In South Africa, for example, This issue describes efforts to develop women make up 90 percent of the HIV- a safe, effective, and acceptable vaginal infected population of 15- to 24-year-olds. microbicide to prevent HIV. Women are at especially high risk of HIV Scientists around the world are working infection because of biologic susceptibility, diligently to develop new ways to prevent HIV, economic dependence on male partners, including vaccines, pre-exposure prophylaxis and inability to negotiate condom use within (when drugs normally used to treat HIV are all of their sexual relationships. A method of used for prevention), and topical microbicides. HIV prevention that a woman could control, Advocacy and support for prevention research such as a vaginal microbicide, could help are strong, and the availability of an effective overcome some of these inequities and save product—although likely years away—could many lives. help alleviate the HIV epidemic in sub-Saharan Africa and worldwide. An effective microbicide could be a powerful addition to current efforts to protect against The Joint United Nations Programme on HIV, including abstinence, mutual monog- HIV/AIDS recently announced that the preva- amy with uninfected partners, condom use, lence of HIV has stabilized or declined in many treatment of sexually transmitted infections, parts of sub-Saharan Africa.
    [Show full text]
  • Next Steps 1% Tenofovir Gel
    DRAFT Next steps 1% Tenofovir Gel Meeting report Johannesburg, South Africa 25–26 August 2010 Department of Reproductive Health and Research Next Steps with 1% Tenofovir Gel Meeting Report Johannesburg, South Africa 25‐26 August 2010 23 November 2010 Next Steps with 1% Tenofovir Gel WHO/UNAIDS Meeting Report 13 January 2011 ii Next Steps with 1% Tenofovir Gel WHO/UNAIDS Meeting Report 13 January 2011 Executive Summary The results of the CAPRISA 004 trial, released in July 2010, showed that 1% tenofovir gel reduced the risk of HIV infection in women by 39% compared with placebo, and by 54% in the women who reported more consistent gel use. These results were historic. After nearly two decades of research,s thi was the first clinical trial to show that a vaginal microbicide could provide a safe and effective way to prevent sexual transmission of HIV. The gel also provided a 51% protective effect against herpes simplex virus type 2 infection (HSV‐2). The announcement raised questions about the most appropriate next steps: making the gel available to women at risk based on this single trial; planning and implementing additional trials to confirm the results; or waiting for the results of the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial, another trial of 1% tenofovir gel using a different dosing strategy. To identify priority next steps, WHO and UNAIDS convened a meeting on 25‐26 August 2010 that drew together more than 80 diverse stakeholders from a range of countries. The meeting, hosted by the South African Department
    [Show full text]
  • PMPA Gel (TMC120) (N=2) TOTAL “51” (N=2) Discovery/Early Preclinical “44” Advanced Preclinical “7”
    Moving Forward with ART Based Microbicides Sharon L. Hillier, Ph.D. University of Pittsburgh School of Medicine OVERVIEW: The Microbicide Pipeline Clinical Development (for HIV) Preclinical Discovery Preclinical Virology Studies 1 2 3 •ACIDFORM™/ •Carraguard Preclinical Development Amphora™ •PRO 2000 •PC 815 (N=2) • Vaginal defense enhancers 6 •UC-781 • Surface-active /membrane-disruption •VivaGel™/ agents 1 SPL7013 (N=4) • Entry/fusion inhibitors 33 1/2 • Replication inhibitors 2 2B • Combinations 8 •Invisible •BufferGel® Condom™ •Tenofovir/ • Uncharacterized mechanism 1 •Dapivirine PMPA gel (TMC120) (N=2) TOTAL “51” (N=2) Discovery/early preclinical “44” Advanced preclinical “7” Source: Alliance for Microbicide Development, 9 April 2007 MTN Portfolio Years 1and 2 Study Products Design HPTN-035 PRO-2000, BufferGel Phase 2/2B HPTN-059 Tenofovir (PMPA gel) Phase 2 MTN-004 VivaGel Phase 1 MTN-001 TDF (oral), tenofovir (PMPA Phase 2 gel) MTN-003 TDF, tenofovir gel, ± Phase 2B Truvada MTN-002 Tenofovir Phase 1-pregnant women MTN-015 Seroconverter Protocol Observational ARTs as Topical Microbicides • TMC-120 (Dapavirine): available as gel and ring; being developed by the International partnership for microbicides • PMPA gel (Tenofovir): available as a gel; being development by CONRAD • MIV150: available as gel, just entering phase 1 testing; being developed by the Population Council Redefining The Road to Success for Microbicides in 2007 • More focus on highly potent inhibitors of HIV • Enhance assessment of safety in animal models and tissue explants • Add more assessments of safety in new trials of microbicides • Move toward coitally independent use of microbicides Tenofovir Mechanism • Acyclic nucleoside analog of AMP. • Requires hydrolysis to form tenofovir diphosphate.
    [Show full text]
  • Vaginal Microbicides for Reducing the Risk of Sexual Acquisition of HIV
    Obiero et al. BMC Infectious Diseases 2012, 12:289 http://www.biomedcentral.com/1471-2334/12/289 RESEARCH ARTICLE Open Access Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis Jael Obiero1,2*, Peter G Mwethera1, Gregory D Hussey3,4 and Charles S Wiysonge3,4 Abstract Background: Each year more than two million people are newly infected with HIV worldwide, a majority of them through unprotected vaginal sex. More than half of new infections in adults occur in women. Male condoms and male circumcision reduce the risk of HIV acquisition; but the uptake of these methods is out of the control of women. We therefore aimed to determine the effectiveness of vaginal microbicides (a potential female-controlled method) for prevention of sexual acquisition of HIV in women. Methods: We conducted a comprehensive search of peer-reviewed and grey literature for publications of randomised controlled trials available by September 2012. We screened search outputs, selected studies, assessed risk of bias, and extracted data in duplicate; resolving differences by discussion and consensus. Results: We identified 13 eligible trials that compared vaginal microbicides to placebo. These studies enrolled 35,905 sexually active HIV-negative women between 1996 and 2011; in Benin, Cameroon, Cote d’Ivoire, Ghana, Kenya, Malawi, Nigeria, South Africa, Tanzania, Uganda, Zambia, Zimbabwe, India, Thailand, and the United States of America. A small trial of 889 women found that tenofovir (a nucleotide reverse transcriptase inhibitor) significantly reduces the risk of HIV acquisition (risk ratio [RR] 0.63, 95% confidence intervals [CI] 0.43 to 0.93).
    [Show full text]
  • What Happens Next: Understanding the Results of HPTN 035 and MDP 301 and the Promise of Arvs for HIV Prevention
    CONTACT: Lisa Rossi PHONE: +1- 412-641-8940 +1- 412- 916-3315 (mobile) E-MAIL: [email protected] What Happens Next: Understanding the Results of HPTN 035 and MDP 301 and the Promise of ARVs for HIV Prevention SUMMARY • Both MDP 301 and HPTN 035 were well-designed and well-executed studies that answered the scientific questions they were designed to answer. HPTN 035 was an intermediate-sized study designed to determine the safety of PRO 2000 and BufferGel and establish whether either product showed sufficient promise for further testing in a Phase III trial or for licensure. It found that PRO 2000 was safe and reduced the risk of HIV by 30 percent, a finding that, although encouraging, was not statistically significant – the odds are one in 10 that the result was due to chance rather than to the product itself. As such, HPTN 035 indicated the need for more research. As a Phase III study involving nearly 9,400 women, MDP 301 was designed to give a more definitive answer about PRO 2000, which it did, finding PRO 2000 was safe but not protective against HIV. While these findings are a disappointment, it is important to understand that research is informed just as much from studies with disappointing outcomes as those considered breakthroughs. • By no means do these studies represent the final act. Other promising approaches are being investigated, most notably, those involving antiretrovirals (ARVs). Because ARVs are effective for treatment of HIV there is good reason to think they can work to prevent HIV infection as well.
    [Show full text]
  • Rectal Microbicides: Can We Make Them and Will People Use Them?
    AIDS Behav DOI 10.1007/s10461-011-9899-9 ORIGINAL PAPER Rectal Microbicides: Can We Make Them and Will People Use Them? Ian McGowan Ó Springer Science+Business Media, LLC 2011 Abstract The results of the CAPRISA 004 and iPrEx transmitted infections (STIs) including HIV [1]. The ori- HIV prevention studies have demonstrated that topical or ginal impetus for vaginal microbicide development was to systemic use of antiretroviral agents can significantly provide women with options for HIV prevention in settings reduce the risk of HIV acquisition associated with unpro- where their partners were unwilling to use condoms [2]. tected vaginal or anal sexual intercourse. However, the Years later, the need to also develop a rectal microbicide effect size in these studies was relatively modest and (RM) became clear, given that a significant proportion of product adherence was generally poor. These observations men do not consistently use condoms during anal sex with suggest the need for new approaches to HIV prevention, men or women [3, 4], and that there has consequently been especially for high risk MSM. Rates of lubricant use are little or no decline in the rates of new HIV infections, high in MSM practicing receptive anal sex. Consequently, particularly in men who have sex with men (MSM) [5]. the development of an antiretroviral rectal microbicide gel Unprotected receptive anal intercourse (RAI) is the sexual may provide a safe and effective means of preventing HIV behavior with the highest per act risk of HIV acquisition, infection with an intervention that is likely to have high conferring perhaps 10–20 times more risk than unprotected acceptability among the target population.
    [Show full text]
  • Hptn 035 Q&A
    CONTACT: Lisa Rossi PHONE: +1-412-641-8940 +1-412- 916-3315 (mobile) E-MAIL: [email protected] EMBARGOED FOR MONDAY, FEB. 9 AT 8:30 AM EASTERN/ 3:30 PM AFRICA QUESTIONS AND ANSWERS HPTN 035: A MULTI-CENTER CLINICAL TRIAL EVALUATING THE CANDIDATE MICROBICIDES BUFFERGEL AND PRO 2000 FOR PREVENTION OF HIV 1. What was the aim of HPTN 035? HPTN 035 was a multi-center clinical trial that evaluated the safety and effectiveness of two candidate microbicides, BufferGel® and PRO 2000 (0.5 percent dose) for preventing male-to-female sexual transmission of HIV. 2. What is a microbicide? Microbicides are substances that are intended to reduce or prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically inside of the vagina or rectum. A microbicide can be formulated in many ways, such as a gel or cream or in a vaginal ring. Several candidate microbicides are being tested in clinical trials, although none is yet approved or available for use. 3. Who conducted and funded the study? HPTN 035 was conducted by a team of leading African and U.S. researchers associated with the Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established and funded in 2006 by the National Institute of Allergy and Infectious Diseases (NIAID), with co-funding by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the U.S. National Institutes of Health (NIH). Prior to the establishment of the MTN, the study was conducted by the NIAID-funded HIV Prevention Trials Network (HPTN), from which the study gets its name.
    [Show full text]
  • Safety and Effectiveness of Buffergel and 0.5% PRO 2000 Gel For
    NIH Public Access Author Manuscript AIDS. Author manuscript; available in PMC 2012 April 24. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: AIDS. 2011 April 24; 25(7): 957±966. doi:10.1097/QAD.0b013e32834541d9. Safety and Effectiveness of BufferGel and 0.5% PRO2000 Gel for the Prevention of HIV Infection in Women Professor Salim S Abdool Karim1,2, Professor Barbra A Richardson3, Professor Gita Ramjee4, Professor Irving F Hoffman5, Professor Zvavahera M Chirenje6, Professor Taha Taha7, Dr Muzala Kapina8, Dr Lisa Maslankowski9, Ms Anne Coletti10, Dr Albert Profy11, Dr Thomas R. Moench12, Ms Estelle Piwowar-Manning13, Professor Benoît Mâsse14, Professor Sharon L. Hillier15, and Dr Lydia Soto-Torres16 on behalf of the HPTN 035 Study Team 1 Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, South Africa 2 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA 3 Department of Biostatistics, University of Washington, USA 4 HIV Prevention Research Unit, South African Medical Research Council, South Africa 5 Division of Infectious Diseases, University of North Carolina, USA 6 Department of Obstetrics and Gynecology College of Health Science, University of Zimbabwe, Zimbabwe 7 Bloomberg School of Public Health, Johns Hopkins University, USA 8 Centre for Infectious Disease Research in Zambia, Zambia 9 University of Pennsylvania, USA 10 Family Health International, USA 11 Preclinical and Pharmaceutical Sciences, Endo Pharmaceuticals Solutions, USA 12 ReProtect Inc, Baltimore, Maryland, USA 13 Johns Hopkins University, USA 14 University of Montreal, Canada 15 University of Pittsburgh School of Medicine, USA 16 National Institutes of Health, USA Corresponding and reprint author: Salim S.
    [Show full text]
  • Microbicides for HIV Prevention
    FAMILY HEALTH RESEARCH A forum for putting knowledge into practice JULY 2008 VOLUME 2, ISSUE 2 INSIDE 2 Clinical research update 4 Evaluating tenofovir gel in South Africa 6 Participating in microbicide trials 7 Preparing for microbicides 8 Research and advocacy partnerships infected people in the world live in this region. MICROBICIDES Of these, more than 60 percent are women. FOR HIV Young women are even more disproportion- ately affected. In South Africa, for example, PREVENTION women make up 90 percent of the HIV- infected population of 15- to 24-year-olds. This issue describes efforts to develop a safe, effective, and acceptable Women are at especially high risk of HIV microbicide to prevent HIV. infection because of biologic susceptibility, economic dependence on male partners, and Scientists around the world are working dili- inability to negotiate condom use within all gently to develop new ways to prevent HIV, of their sexual relationships. A method of HIV including vaccines, pre-exposure prophylaxis prevention that a woman could control, such (when drugs normally used to treat HIV are as a topical microbicide, could help overcome used for prevention), and topical microbi- some of these inequities and save many lives. cides. Advocacy and support for prevention research are strong, and the availability of Both vaginal microbicides (for use by an effective product—although likely years women) and rectal microbicides (for use by away—could help alleviate the HIV epidemic women and men) are under development. in sub-Saharan Africa and worldwide. This issue will focus on the vaginal products that have reached clinical trials of effective- The Joint United Nations Programme on HIV/ ness in humans.
    [Show full text]
  • CAPRISA 004 Phase Iib Trial to Assess the Safety and Effectiveness
    CAPRISA 004 Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa Trial design and conduct: Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa, Coordination of Product manufacture and packaging: CONRAD, Virginia, USA Statistical, regulatory and operational support: Family Health International, North Carolina, USA Co-Principal Investigators Quarraisha Abdool Karim, PhD, and Salim S. Abdool Karim, MBChB, PhD CAPRISA, University of KwaZulu-Natal Version 1.3, 29 October 2010 CAPRISA 004 - Version 1.3 Page 1 29 October 2010 Phase IIb trial to assess the safety and effectiveness of the vaginal 1% tenofovir gel for the prevention of HIV infection in women in South Africa PROTOCOL TEAM ROSTER Quarraisha Abdool Karim, PhD Salim S. Abdool Karim, MBChB, FFPHM, PhD Co-Principal Investigator Co-Principal Investigator CAPRISA, Nelson R Mandela School of Medicine, CAPRISA, Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Private Bag 7, University of KwaZulu-Natal, Private Bag 7, Congella 4013, Durban, South Africa Congella 4013, Durban, South Africa [email protected] [email protected] T: 27-31-260 4208 T: 27-31-260 2381 F: 27-31-260 4307 F: 27-31-260 3093 Cheryl Baxter, MSc Janet Frohlich, DipMGC, DCurVulindlela Site Research Associate Operations ManagerCAPRISA Vulindlela Clinical CAPRISA , Nelson R Mandela School of Medicine, Research Site, Mafakatini Primary
    [Show full text]
  • Px Wire: on HIV Prevention Research Volume 3 | No
    A Quarterly Update Px Wire: on HIV Prevention Research Volume 3 | No. 1 January–March 2010 Despite disappointing results, there is still much to AVAC’s Take be learned from this trial. Spanning four years and four countries—South Africa, Tanzania, Uganda and Zambia— The last three months of 2009 took us to an unprecedented MDP 301 can serve as a model for future HIV prevention place in the field of HIV prevention research. For the first trials. In addition to critical scientific information, it will time in history, a clinical trial showed that the prevention provide important data from its extensive social science of HIV through vaccination is possible. Researchers also component and lessons from the comprehensive discovered the first new neutralizing antibodies in over a community engagement and preparation undertaken decade that may be helpful in the creation of new vaccine by the trial staff. candidates. At the same time, news from microbicide and MDP 301 also underscores the need to continue the PrEP trials provided reminders of the challenges and search for new laboratory assays and animal models for complexities of biomedical HIV prevention trials. assessing safety and finding correlates of protective efficacy In the broader world of HIV/AIDS, the US government in humans. In both animal studies and the laboratory, repealed the decades-long bans on federal funding for Continues on back syringe exchange and on entry to the US for people with HIV. Both of these moves represent important steps forward for evidence-based HIV prevention. Looking ahead in 2010, we anticipate a cascade of safety At a Glance and adherence data from oral PrEP trials; results from a phase IIb trial of tenofovir gel; the launch of new trials • In October, the US National Institute of Allergy and looking at intermittent PrEP and the “test-and-treat” Infectious Diseases (NIAID) held a workshop, Beyond strategy; and other events we can’t predict.
    [Show full text]
  • 1 PRO2000 Vaginal Gel for the Prevention of HIV Infection
    PRO2000 vaginal gel for the prevention of HIV infection: results of the MDP301 Phase III randomised microbicide trial Sheena McCormack MSc MRC Clinical Trials Unit, London UK Gita Ramjee PhD MRC HIV Prevention Research Unit, Durban, South Africa Anatoli Kamali MSc MRC/UVRI Uganda Research Unit, Entebbe, Uganda Helen Rees MRCGP RHRU, University of the Witwatersrand, Johannesburg, South Africa Angela Crook PhD MRC Clinical Trials Unit, London UK Mitzy Gafos MSc Africa Centre for Health and Population Studies, South Africa Ute Jentsch PhD CLS, University of the Witwatersrand, Johannesburg, South Africa Robert Pool PhD University of Barcelona, Barcelona, Spain & University of Amsterdam, The Netherlands Maureen Chisembele MBBS University Teaching Hospital, Lusaka, Zambia Saidi Kapiga MD Mwanza Intervention Trials Unit (MITU), Mwanza, Tanzania Richard Mutemwa PhD London School of Hygiene and Tropical Medicine, London, UK Andrew Vallely PhD London School of Hygiene and Tropical Medicine, London, UK Thesla Palanee PhD RHRU, University of the Witwatersrand, Johannesburg, South Africa Yuki Sookrajh MBChB MRC HIV Prevention Research Unit, Durban, South Africa Charles J Lacey MD University of York, UK Janet Darbyshire MSc MRC Clinical Trials Unit, London UK Heiner Grosskurth PhD MRC/UVRI Uganda Research Unit, Entebbe, Uganda Albert Profy PhD Endo Pharmaceuticals Solutions, Inc., Chadds Ford, Pennsylvania, USA Andrew Nunn MSc MRC Clinical Trials Unit, London UK Richard Hayes DSc London School of Hygiene and Tropical Medicine, London, UK Jonathan Weber PhD Imperial College, London, UK Address for Correspondence Dr Sheena McCormack MRC Clinical Trials Unit 222 Euston Road London, NW1 2DA, UK Tel: +44 2076704703 1 Abstract Background: There is an urgent need for effective HIV prevention strategies such as vaginal microbicides that can be used by women.
    [Show full text]